CureVac is threatened with a vaccine flop at the second attempt

But the hype ended abruptly when CureVac failed with its corona vaccine in June 2021. In the pivotal study, the Tübingen company’s vaccine was only 48.2 percent effective. The share price fell by more than 75 percent, to the chagrin of the shareholders, including SAP co-founder Dietmar Hopp (46 percent) and the federal government (16 percent).

It’s a heavy defeat. Biontech and Mainz won the vaccine race fabulously. CureVac and Tübingen lost it spectacularly.